Clinical Trial Update: A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating farletuzumab with carboplatin/paclitaxel or carboplatin/PLD in platinum-sensitive ovarian cancer in first relapse; study completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-sensitive Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Farletuzumab (farletuzumab)
• PACLITAXEL (PACLITAXEL)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Eisai Inc. | Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse | Phase 2 | Status: COMPLETED | Results posted: 2021-09-02